舒尼替尼对晚期肾癌具有一定疗效  

Sunitinib Has a Certain Effect on the Treatment of Advanced Renal Cancer

作　　者：唐兴国[1] 李斌斌[1] 刘宏伟[1] Tang Xingguo;Li Binbin;Liu Hongwei(Department of Anatomy,Chengde Nursing Vocational College,Chengde,067000)

机构地区：[1]承德护理职业学院人体解剖学教研室

出　　处：《基因组学与应用生物学》2019年第8期3798-3802,共5页Genomics and Applied Biology

摘　　要：为探讨舒尼替尼对晚期肾癌的治疗效果,本研究选取晚期肾癌患者61例,均给予舒尼替尼标准治疗,观察患者治疗疗效及不良反应情况。研究结果发现,截止随访结束日,可评价疗效50例,其中部位缓解(partial remission, PR)者13例(26.00%),疾病稳定(stable of disease, SD)者20例(40.00%),疾病进展(progression of disease, PD)者17例(34.00%),无完全缓解(complete remission, CR)患者;患者中位无进展生存时间为15个月;患者不良反应主要包括腹泻、中性粒细胞降低、手足反应和皮肤黄染,比例分别为68.85%、59.02%、54.10%和52.46%;不良反应级别以Ⅰ~Ⅱ级为主,Ⅲ~Ⅳ级较少见。本研究初步结论表明,舒尼替尼对晚期肾癌有一定的疗效。本研究认为治疗期间应给予患者科学性护理措施及建议,以提高患者不良反应的耐受性。To investigate the effect of sulnitinib in the treatment of advanced renal cancer, we selected 61 patients with advanced renal cell carcinoma who were treated in our hospital from December 2015 to October 2017. All patients were treated with sunitinib standard treatment, the curative effect and adverse reactions were observed.The results of the study showed that 50 cases were evaluable for curative effect, of which 13 cases(26%) were partial remission(PR), 20 cases(40%) were stable of disease(SD), 17 cases(34%) were progression of disease(PD), and no complete remission(CR) in the end of January 2018;There were no significant difference in the curative effect of the patients with different sex, age and distant metastasis(p<0.05);The median progression free survival time of the patients was 15 months;The main adverse reactions of the patients were diarrhea, neutrophils decreased, hand foot reaction and skin stained yellow, which were 68.85%, 59.02%, 54.10% and 52.46%;The grade of adverse reaction was mainly grade Ⅰ to grade Ⅱ, and was rare in grade Ⅲ to Ⅳ. The preliminary conclusions of this study indicated that sunitinib should have certain efficacy in the treatment of advanced renal cell carcinoma. We believed that scientific nursing measures and consultancy should be given to patients during treatment to improve the tolerance of patients’ adverse reactions.

关 键 词：舒尼替尼 晚期肾癌 疗效评价 护理对策 

分 类 号：R73[医药卫生—肿瘤]